Mild cognitive impairment Cognitive dysfunction, Memory loss, Amnesia, Dementia, Alzheimers disease
Conditions
Sponsors
Osawa Ryota
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Individuals aged between 50 and 85 years at the time of consent acquisition. 2) Individuals with an MMSE score of 22 or above. 3) Individuals with a CDR score of 0.5 or 1.0. 4) Individuals with confirmed accumulation of amyloid beta through amyloid PET imaging. 5) Individuals who are eligible for anti-amyloid-beta antibody therapy but did not wish to receive the treatment. 6) Individuals for whom anti-amyloid-beta antibody therapy is difficult to apply due to medical reasons such as contraindications. 7) Individuals deemed capable of providing written consent by their attending physician. 8) Individuals able to attend outpatient visits for TMS treatment.
Exclusion criteria
Exclusion criteria: 1) Individuals with organic brain diseases (moderate or severe intracranial structural lesions). 2) Individuals with a history of seizures or epilepsy. 3) Individuals with unstable physical conditions (e.g., heart failure or renal failure). 4) Individuals with mental instability severe enough to hinder outpatient visits. 5) Individuals with contraindications to TMS, such as metal implants in the head or neck or a cardiac pacemaker. 6) Individuals deemed unsuitable for participation in the study by the principal investigator or co-investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in CDR-SB score before and after the novel TMS treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in the following items before and after the novel TMS therapeutic intervention - MMSE - DASC-21 - TMT | — |
Contacts
Public ContactYoshihiro Noda
International University of Health and Welfare
Outcome results
None listed